Department of Neurosurgery, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
Neurosurgery. 2022 Mar 1;90(3):329-339. doi: 10.1227/NEU.0000000000001822. Epub 2022 Jan 18.
There is a gap in understanding how to ensure opioid stewardship while managing postoperative neurosurgical pain.
To describe self-reported opioid consumption and pain intensity after common neurosurgery procedures gathered using an automated text messaging system.
A prospective, observational study was performed at a large, urban academic health system in Pennsylvania. Adult patients (≥ 18 years), who underwent surgeries between October 2019 and May 2020, were consented. Data on postoperative pain intensity and patient-reported opioid consumption were collected prospectively for 3 months. We analyzed the association between the quantity of opioids prescribed and consumed.
A total of 517 patients were enrolled. The median pain intensity at discharge was 5 out of a maximum of pain score of 10 and was highest after thoracolumbar fusion (median: 6, interquartile range [IQR]: 4-7). During the follow-up period, patients were prescribed a median of 40 tablets of 5-mg oxycodone equivalent pills (IQR: 28-40) and reported taking a median of 28 tablet equivalents (IQR: 17-40). Responders who were opioid-naive vs opioid-tolerant took a similar median number of opioid pills postoperatively (28 [IQR: 17-40] vs 27.5 [17.5-40], respectively). There was a statistically significant positive correlation between the quantity of opioids prescribed and used during the 3-month follow-up (Pearson R = 0.85, 95% CI [0.80-0.89], P < .001). The correlation was stronger among patients who were discharged to a higher level of care.
Using real-time, patient-centered pain assessment and opioid consumption data will allow for the development of evidence-based opioid prescribing guidelines after spinal and nerve surgery.
在管理术后神经外科疼痛的同时,如何确保阿片类药物的管理是一个尚未解决的问题。
描述使用自动短信系统收集的常见神经外科手术后患者自我报告的阿片类药物使用量和疼痛强度。
在宾夕法尼亚州的一个大型城市学术医疗系统中进行了一项前瞻性、观察性研究。纳入 2019 年 10 月至 2020 年 5 月期间接受手术的成年患者(≥ 18 岁),并获得其同意。前瞻性收集术后 3 个月的疼痛强度和患者报告的阿片类药物使用量数据。我们分析了开具的阿片类药物数量与实际使用量之间的关系。
共纳入 517 例患者。出院时的疼痛强度中位数为 10 分制中的 5 分,胸腰椎融合术后最高(中位数:6,四分位距 [IQR]:4-7)。在随访期间,患者平均开具 40 片 5mg 羟考酮等效药片(IQR:28-40),报告平均服用 28 片等效药片(IQR:17-40)。初次使用阿片类药物的患者与耐受阿片类药物的患者术后服用的阿片类药物中位数数量相似(28 [IQR:17-40] vs 27.5 [17.5-40])。在 3 个月的随访期间,开具的阿片类药物数量与实际使用量之间存在显著的正相关(Pearson R = 0.85,95%CI [0.80-0.89],P <.001)。在出院至更高护理水平的患者中,相关性更强。
使用实时的、以患者为中心的疼痛评估和阿片类药物使用数据,将有助于制定脊柱和神经手术后基于证据的阿片类药物处方指南。